Sue Hughes is a medical journalist with over 20 years of experience. She currently writes for Medscape and MDEdge, covering a wide range of topics in cardiology and neurology. Her articles provide valuable insights into the latest research, treatment options, and developments in the medical field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Not enough data
Sue Hughes' articles predominantly focus on healthcare and pharmaceuticals, particularly in the realms of migraine treatment, CGRP inhibitors, hypertension, and cardiovascular risk. Her coverage mainly cites data to support her insights.
If reaching out to Sue with a pitch or as a source, consider providing scientifically backed information on new developments in these fields or offering access to experts who can provide detailed analysis based on verifiable data. This could involve sharing new clinical trial results or evidence-based research findings related to the topics she covers.
Since Sue primarily focuses on citing data in her articles, it would be beneficial to emphasize any statistics or scientific studies that back up your pitches when reaching out for potential collaboration.
This information evolves through artificial intelligence and human feedback. Improve this profile .
With growing evidence that loneliness increases the risk for multiple diseases, there are questions about the mechanisms at play and what clinicians can do to help patients.
CHICAGO — A new study has shown for the first time that a drug therapy can reduce major heart failure clinical outcomes in patients with heart failure and a preserved ejection fraction (HFpEF) and obesity
Aspirin may be of specific benefit for the primary prevention of cardiovascular disease in individuals with raised Lp(a) levels, a new study has suggested.
CHICAGO — An intensive treatment approach to lower systolic blood pressure to a target of 120 mm Hg in patients with type 2 diabetes led to a lower
The routine administration of spironolactone to patients after a myocardial infarction (MI) did not reduce either of the coprimary outcomes in the CLEAR SYNERGY (OASIS 9) trial.
Edoxaban was at least as effective as warfarin in preventing thromboembolism after bioprosthetic valve replacement in the ENBALV trial, but the event rate was too low to draw definitive conclusions.
The risk of arterial and venous thrombosis in patients with COVID-19 has been a major issue throughout the pandemic, and how best to manage this risk is the subject of a new review article.
A new lipid-lowering agent in a class that had been written off by many is being developed by a group of academic experts, with new data showing large LDL reductions on top of high-intensity statins.
Do We Need Cardiovascular Risk Equations to Guide Statin Use?
An individual's estimated risk of having a heart attack or stroke in the next 10 years is widely used to guide preventative medication prescriptions
(833) 317-6278 
